Skip to main
BMY

Bristol-Myers (BMY) Stock Forecast & Price Target

Bristol-Myers (BMY) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 29%
Buy 24%
Hold 41%
Sell 6%
Strong Sell 0%

Bulls say

Bristol-Myers Squibb is expected to have a strong quarter driven by growth products such as Opdivo and Qvantig, as well as continued growth in Eliquis. The team is confident in the company's 10-15% growth target for Eliquis for the year, with a focus on cost considerations. With upcoming clinical readouts and potential label expansions, Bristol-Myers Squibb has the opportunity for multiple expansion and is a buy according to analysts, with a target price of $72.

Bears say

Bristol-Myers Squibb is facing downside risks due to potential competition in its key therapeutic areas, clinical failures in their pipeline, and potential regulatory delays. With 70% of total sales coming from the US, the company is highly exposed to any changes in the US market, posing additional macro/policy-related risks. Despite its strong position in the immuno-oncology market, these risks could lead to a negative outlook on the company's stock.

Bristol-Myers (BMY) has been analyzed by 17 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 24% recommend Buy, 41% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bristol-Myers (BMY) Forecast

Analysts have given Bristol-Myers (BMY) a Buy based on their latest research and market trends.

According to 17 analysts, Bristol-Myers (BMY) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $65.76, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $65.76, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bristol-Myers (BMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.